Home > Healthcare & Medical Devices > Insulin Delivery Devices Market

Insulin Delivery Devices Market Size By Product (Insulin Pumps {Tubed/Tethered Pumps, Tubeless Pumps}, Insulin Pens {Reusable, Disposable}, Insulin Pen Needles {Standard, Safety}, Insulin Jet Injectors, Insulin Syringes), By End-use (Home Care, Hospitals & Clinics), Industry Analysis Report, Regional Outlook, Covid-19 Impact Analysis, Application Development Potential, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI1649
  • Published Date: Apr 2022
  • Report Format: PDF

Industry Overview

Insulin Delivery Devices Market size surpassed USD 14.7 billion in 2021 and is estimated to register over 7% CAGR between 2022 and 2028. The growing prevalence of diabetes is the key factor promoting the market growth. The increased prevalence of diabetes has also contributed to the surging mortality rate.

Get more details on this report - Request Free Sample PDF

For instance, according to the World Health Organization (WHO), in 2019, diabetes was amongst the leading cause of mortality with approximately 1.5 million deaths directly caused by this disease. In addition to this, the rising healthcare expenditure and growing adoption of novel insulin delivery devices in emerging economies is anticipated to have a positive impact on market statistics.

Insulin delivery devices are used to administer insulin in the body. These devices are used by patients suffering with advanced type 2 diabetes mellitus (T2DM) and all patients with type 1 diabetes mellitus (T1DM) to maintain the blood glucose levels. These insulin delivery devices include syringes, pens, pen needles, jet injectors, and others.

However, high out-of-pocket expenditure in emerging economies and stringent government regulations may negatively impact the market growth. Diabetes is chronic & progressive condition in nature and inflicts significant financial burden on the healthcare system. In developing countries, the high out-of-pocket expenditure associated with diabetes treatment & management may affect the adoption rate of insulin delivery devices.

Also, the high expenses associated with the treatment results in poor adherence to prescribed therapy that undermines the benefits of the therapeutics and accounts for 30%–50% of treatment failures. Furthermore, the U.S. FDA overlooks the development, approval, and post-approval surveillance associated with insulin delivery devices.

Certain devices, for instance the insulin pumps are classified as Class II & III medical devices that are mandated to undergo strict regulatory approval process & compliances. Thus, rigid regulatory framework & high cost may impede the insulin delivery devices industry growth.

The COVID-19 emerged as a global health crisis and had a slightly negative impact on the insulin delivery devices market growth, during the first half of 2020. To limit the spread of the transmission, nation-wide lockdowns and emergencies were imposed in various countries globally. The shutdown and restraints on movement impacted the healthcare practices including diabetes management.

According to the WHO report, in 2020, approximately half of the countries stated complete or partial disruptions associated with diabetic complication management services (49%). These disruptions were even higher in the lower & middle-income countries.

Also, few major market players also reported a slight decline in the revenue growth owing to business disruption following the COVID-19 pandemic. However, patients suffering from type 1 diabetes (T1D) are considered as more vulnerable when infected with SARS-CoV-2 virus. As a result, several public organizations, governing authorities, and market players took initiatives to endure seamless supply of diabetes management essentials, including insulin & insulin delivery devices.

As per the American Diabetes Association (ADA), the use of diabetes technology including tubeless insulin pumps is recommended to improve glycaemic control in diabetic COVID-19 patients. Various government authorities including the U.S. federal agencies accelerated the authorization in clinical practice to allow teleconsultation, thereby balancing the drawbacks of hospital visits during the pandemic.

Market players have initiated a patient assistance program for patients that have lost their insurance coverage. For instance, Medtronic has introduced the Medtronic COVID-19 Payment Relief Program for the applicable product including insulin pumps to aid Canadian diabetes customers that are not eligible to receive government program funding. These collaborative efforts are expected to uplift the market demand in the coming years.

Growing prevalence of diabetes will amplify the market expansion

The rising prevalence of diabetes is the major factor augmenting the need for insulin delivery devices. With the surging patient population, the industry is expected to witness significant growth pertaining to the rising preference for insulin delivery devices owing to their reliability and patient satisfaction.

According to the International Diabetes Federation (IDF), the overall number of diabetic individuals is expected to surge by 51% from 463 million in 2019 to 700 million by 2045. In the U.S., the Centers for Disease Control and Prevention (CDC) states that in 2021, around 37.3 million people were suffering from diabetes. The increasing prevalence of diabetes patients globally is set to proliferate the demand for insulin delivery devices, thereby accelerating the market statistics.

The surge in the prevalence of type 1 diabetes mellitus would also prove beneficial for the market growth. Patients suffering with type 1 diabetes are characterized by the body’s inability to produce insulin and mandate intensive insulin therapy to survive. According to the National Centers for Biotechnology Information (NCBI), in 2020, the prevalence of type 1 diabetes was 5.9 per 100,000 population.

The insulin delivery devices offer a simplified and efficient solution to patients for insulin administration & diabetes management. Thus, the rising prevalence of diabetes is anticipated to accelerate the demand for insulin delivery devices for insulin administration.

Higher preference for insulin pens segment leads to its market dominance

Get more details on this report - Request Free Sample PDF

Based on product, the market is segmented as insulin pumps, insulin pens, insulin pen needles, insulin jet injectors, insulin syringes, and others. The insulin pens segment is anticipated to reach more than USD 12,698 million by 2028. This high market share is owing to the high preference for insulin pen, several benefits offered by insulin pens at affordable cost, and technological advancements among others.

Several clinical studies have confirmed that insulin pens offer considerable advantage over syringes. These clinical advantages include greater precision, ease of use, enhanced quality of life, patient satisfaction, and adherence.

The U.S. claims database analyses highlight the enhanced adherence associated with the use of an insulin pen and has the potential to limit the financial burden of diabetes as compared with a vial & syringe. As per the Novo Nordisk, around two-thirds of insulin volumes are injected using an insulin pen device. Further, technological advancements and the development of smart pen is also anticipated to drive the adoption of insulin pens.

Growing adoption of insulin delivery devices in home care settings is expected to surge the industry demand

Get more details on this report - Request Free Sample PDF

Based on end-use, the insulin delivery devices market is segmented as home care, hospitals & clinics, and others. The home care segment held more than USD 8,285 million in 2021. This significant market share is owing to growing adoption of these devices in the home care settings. The increasing pressure to reduce incremental healthcare expenses associated with diabetes management, significant advancements, and availability of easy-to-use devices would drive the market outlook.

Moreover, the development of novel solutions including smart insulin pen is set to promote the adoption rate of these devices in home care settings. The smart insulin pen features a reusable injector pen with a supporting smartphone application that aids in efficient management of insulin delivery. This smart insulin pen estimates and tracks the insulin doses & offers helpful reminders, alerts, and reports. Thus, the launch of novel products that offer ease in use are set to promote the product adoption in home care settings, thereby driving the market statistics.

High product acceptance & technological advancements in the North America region to curb the diabetes burden will promote the regional business demand

Get more details on this report - Request Free Sample PDF

U.S. insulin delivery devices market is anticipated to cross USD 9,516 million by 2028. This dominant market share is attributable to several factors such as high acceptance of advanced insulin delivery equipment, significant diabetes burden, exponential healthcare spending, and adoption of facilitative initiatives by the governing authorities across the country.

According to the CDC, in 2019, around 28.7 million or 8.7% of the U.S. population was diagnosed with diabetes. Approximately, 1.6 million adults, equating to 5.7% of the U.S. population was suffering from type 1 diabetes and using insulin therapy. The significant diabetic population has led to increased diabetes expenditure. As per the NCBI article, in 2019, the U.S. diabetes care expenditure accounted for USD 294.6 billion. The increased diabetes expenditure would drive the adoption of novel insulin delivery solutions in the country.

Strategies adopted by major market players will surge the industry expansion

Some of the major players operating in the insulin delivery devices industry are Sanofi, Becton, Dickinson and Company (BD), Eli Lilly, Novo Nordisk, Roche, Insulet Corporation, Medtronic, Tandem Diabetes Care, and Ypsomed among others. These prominent players focus on strategic partnerships, new product launch & commercialization for industry expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue.

Recent industry developments:

  • In March 2022, Novo Nordisk announced the launch of its smart insulin in the UK, offering people treated within the NHS for diabetes access to devices. This novel product launch will offer competitive advantage and strengthen its industrial position in the UK region.
  • In November 2020, Medtronic launched the InPen smart insulin pen that is integrated with real-time Guardian Connect CGM data. This integrated mechanism offers real-time glucose readings coupled with insulin dose data, making it easier to make smarter dosing decisions. This product launch assisted the company in driving the sales & revenue generation in insulin delivery devices market.

Insulin delivery devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

By Product

  • Insulin Pumps
    • Tubed/Tethered
    • Tubeless
  • Insulin Pens
    • Reusable
    • Disposable
  • Insulin Pen needles
    • Safety
    • Standard
  • Insulin Jet Injectors
  • Insulin Syringes
  • Others

By End-use

  • Home Care
  • Hospitals & clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia 
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Egypt


Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for insulin delivery devices exceeded USD 14.7 billion in 2021 and is expected to expand at a CAGR of 7% from 2022 to 2028 owing to the rising prevalence of diabetes.
U.S. market for insulin delivery devices is estimated to cross USD 9,516 million until 2028 driven by the high acceptance of advanced insulin delivery equipment, exponential healthcare spending, and significant diabetes burden.
Insulin delivery devices industry share from insulin pens is poised to surpass USD 12,698 million by 2028 considering the rising technological advancements and the high preference for insulin pen.
Leading players in the insulin delivery devices industry comprise Tandem Diabetes Care, Novo Nordisk, Sanofi, Roche, Medtronic, Insulet Corporation, and others.

Buy Now

Premium Report Details

  • Base Year: 2021
  • Companies covered: 22
  • Tables & Figures: 294
  • Countries covered: 18
  • Pages: 130
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount